Literature DB >> 11975686

Malignant mixed Mullerian tumor of the uterine cervix with neuroendocrine differentiation.

Alfredo Ribeiro-Silva1, A Novello-Vilar, A M Cunha-Mercante, L A L De Angelo Andrade.   

Abstract

Malignant mixed Mullerian tumors (MMMTs) are rare neoplasms. We report the clinical, pathologic, and immunohistochemical features of an MMMT primary of uterine cervix. This lesion was composed of a poorly differentiated epithelial component (cytokeratin positive) and a spindle cell component (vimentin positive) with heterologous (myoblastic) differentiation (focal 1A4 positive). There were also cells with neuroendocrine features that expressed S-100 and chromogranin A. Along with a brief review of this amazing neoplasm, some histogenetic concepts relevant to this case are discussed. To our knowledge this is the first report of a malignant mixed Mullerian tumor of the uterine cervix with neuroendocrine differentiation.

Entities:  

Mesh:

Year:  2002        PMID: 11975686     DOI: 10.1046/j.1525-1438.2002.01100.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Malignant mixed mullerian tumour, heterologous in a 66-year-old malay lady - a case report.

Authors:  Md Tahminur Rahman; Venkatesh R Naik; Shah Reza Johan Noor; Nik Mohamed Zaki Nik Mahmud; Mohd Isa
Journal:  Malays J Med Sci       Date:  2003-07

Review 2.  Cervical Carcinosarcoma: Current Understanding on Pathogenesis, Diagnosis, Management and Future Perspectives.

Authors:  Xinyao Shu; Yuwen Zhou; Guixia Wei; Xiaorong Chen; Meng Qiu
Journal:  Clin Med Insights Oncol       Date:  2021-12-08

3.  Malignant müllerian mixed tumor of the uterine cervix with a small cell neuroendocrine carcinoma component.

Authors:  Satoru Munakata; Emi Iwai; Tomohito Tanaka; Michihiko Nakamura; Takayoshi Kanda
Journal:  Case Rep Pathol       Date:  2013-02-26

4.  Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

Authors:  Clemens B Tempfer; Iris Tischoff; Askin Dogan; Ziad Hilal; Beate Schultheis; Peter Kern; Günther A Rezniczek
Journal:  BMC Cancer       Date:  2018-05-04       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.